NCT05913908RecruitingNot Applicable
Early Feasibility Study of the DUO Transcatheter Tricuspid Coaptation Valve System in Patients With Tricuspid Regurgitation
CroiValve Limited32 sites in 2 countries15 target enrollmentStarted: August 13, 2024Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 15
- Locations
- 32
- Primary Endpoint
- Freedom from device or procedure related MAEs
Study Overview
Brief Summary
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Detailed Description
Multi-center, prospective, non-randomized, investigational, and pre-market. Data collected in this clinical study will include safety and function of the investigational system as well as up to 5 year clinical outcomes.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Presence of severe or greater tricuspid regurgitation as determined by the Echo Core Lab.
- •Patient is symptomatic despite medical therapy.
- •The local Site Heart Team determines the Patient is appropriate for transcatheter valve intervention.
- •The Patient's anatomy is suitable in the judgment of the Patient Selection Committee.
- •Age ≥18 years
- •The Patient has been informed of the nature of the study and agrees to its provisions and has provided written Informed Consent.
Exclusion Criteria
- •Patient is currently participating in another clinical investigation that could affect the outcome of this trial.
- •Any previous tricuspid valve intervention that would interfere with the placement of the investigational device.
- •Moderate or greater tricuspid valve stenosis.
- •Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation
- •Pacemaker or implantable cardioverter-defibrillator (ICD) leads that would prevent appropriate placement of the investigational device.
- •Need for concomitant surgical or interventional procedure, known at the time of screening (e.g., CABG, Atrial Septal Defect (ASD) repair).
- •Ejection Fraction (EF) <25%
- •Echocardiographic evidence of unstable intracardiac mass, thrombus or vegetation
- •Patient has Systolic Pulmonary Pressure (sPAP) >60 mm Hg
- •Severe hemodynamic instability: cardiogenic shock or the need for inotropic support or Intra-Aortic Balloon Pump (IABP) or other percutaneous ventricular assist devices
- •Severe respiratory instability with continuous use of home oxygen
- •Severe right ventricular dysfunction
- •Untreated clinically significant coronary or carotid artery disease requiring revascularization surgical or interventional PCI.
- •Stroke or transient ischemic event within 90 days prior to the index procedure
- •Acute myocardial infarction within 30 days before the index procedure
- •Renal insufficiency (eGFR <25 ml/min) or currently on chronic dialysis
- •Active endocarditis within 6 months of the index procedure
- •Pulmonary embolism or deep vein thrombosis within the last 6 months
- •Any surgical, interventional, or transcatheter procedure within 30 days prior to the index procedure
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis
- •Life expectancy <1 year
- •Active infections requiring current antibiotic therapy
- •Known severe liver disease
- •Is on the waiting list for a transplant or has had a prior heart or lung transplant
- •Known active peptic ulcer or active GI bleed
- •Unable to take anticoagulant therapy
- •Any known major coagulation abnormalities, thrombocytopenia, platelets < 50,000/ml or severe anemia Hb <8 g/dl
- •Known patient is actively abusing drugs
- •Any known sensitivities or allergies to contrast (that cannot be adequately premedicated) and/or the device materials, including nickel and titanium
- •Patients who are pregnant or intend to become pregnant
- •Any condition making it unlikely the Patient will be able to complete all protocol procedures (including compliance with optimal medical therapy and immobility that would prevent completion of 6MWT), follow-up visits, or impact the scientific soundness of the clinical investigation result
Arms & Interventions
Treatment
Experimental
Treatment with the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System)
Intervention: DUO Transcatheter Tricuspid Coaptation Valve System (Device)
Outcomes
Primary Outcomes
Freedom from device or procedure related MAEs
Time Frame: At 30 days
* Death * Reintervention * Disabling stroke * Myocardial infarction * Major access site and vascular complications * Severe bleeding * Renal failure requiring dialysis * Major cardiac structural complications * Pulmonary embolism
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (32)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
TTVR Early Feasibility StudyTricuspid RegurgitationNCT04433065Medtronic Cardiovascular150
Withheld
Not Applicable
[Trial of device that is not approved or cleared by the U.S. FDA]NCT06737978[Redacted]15
Completed
Not Applicable
Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic SubjectsDiabetes Mellitus, Type 2NCT04285554Metavention15
Recruiting
Not Applicable
Early Feasibility Study of the Cardiac Implants Percutaneous Ring Annuloplasty SystemTricuspid Regurgitation FunctionalNCT04890821Cardiac Implants LLC15
Completed
Not Applicable
Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep ApneaObstructive Sleep ApneaOSANCT05881512Somnial Inc12